Effect of dipyridamole on myocardial reperfusion injury: A double‐blind randomized controlled trial in patients undergoing elective coronary artery bypass surgery. Issue 4 (22nd October 2015)

• Record Type: Journal Article
• Authors: El Messaoudi, S; Wouters, CW; van Swieten, HA; Pickkers, P; Noyez, L; Kievit, PC; Abbink, EJ; Rasing‐Hoogveld, A; Bouw, TP; Peters, JG; Coenen, MJH; Donders, ART; Riksen, NP; Rongen, GA
• Is Part Of: Clinical pharmacology & therapeutics. Volume 99:Issue 4(2016:Apr.)
• Page Start: 381
• Page End: 389
• Publication Date: 2015-10-22
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.106
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : Dipyridamole reduces reperfusion‐injury in preclinical trials and may be beneficial in patients undergoing coronary angioplasty, but its effect on patients undergoing coronary artery bypass grafting (CABG) is unknown. We hypothesized that dipyridamole limits myocardial reperfusion‐injury in patients undergoing CABG. The trial design was a double‐blind trial randomizing between pretreatment with dipyridamole or placebo. In all, 94 patients undergoing elective on‐pump CABG were recruited between February 2010 and June 2012. The primary endpoint was plasma high‐sensitive (hs‐) troponin‐I at 6, 12, and 24 hours after reperfusion. Secondary endpoints were the occurrence of bleeding, arrhythmias, need for inotropic support, and intensive care unit length of stay. Finally, 79 patients (33 dipyridamole) were included in the per‐protocol analysis. Dipyridamole did not significantly affect postoperative hs‐troponin‐I (change in plasma hs‐troponin I −3% [95% confidence interval −23% to 36%]; P > 0.1). Secondary endpoints did not differ between groups. Dipyridamole prior to CABG does not significantly reduce postoperative hs‐troponin release.